About
About ShanXi C&Y Pharmaceutical Group Co., Ltd
ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, smoking cessation drugs, pediatric drugs, respiratory system drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, nephropathy drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. The company's product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsules, Cinacalcet hydrochloride tablets, Apixaban tablets, Rivaroxaban tablets, Fluoxetine hydrochloride capsules, Ambroxol hydrochloride dispersible tablets, Montmorillonite powder, Varenicline tartrate tablets, Vitamin AD drops, and Baoling Yunbao oral liquid, as well as salt acid glucosamine raw material product. It also provides medical and health services and commercial services, such as medical diagnosis, gene preservation, and pregnancy environment testing services. The company was formerly known as Shanxi C&Y Pharmaceutical Co., Ltd. and changed its name to ShanXi C&Y Pharmaceutical Group Co.,LTD. in September 2014. The company was founded in 2005 and is based in Xuhui, China.
Research context
ShanXi C&Y Pharmaceutical Group Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
ShanXi C&Y Pharmaceutical Group Co., Ltd is currently in a long term downtrend where the price is trading 1.6% below its 200 day moving average.
From a valuation standpoint, the stock is 85.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.4.
ShanXi C&Y Pharmaceutical Group Co., Ltd's total revenue sank by 21.6% to $205M since the same quarter in the previous year.
Its net income has dropped by 26.6% to $-48M since the same quarter in the previous year.
Finally, its free cash flow fell by 84.9% to $4M since the same quarter in the previous year.
Based on the above factors, ShanXi C&Y Pharmaceutical Group Co., Ltd gets an overall score of 1/5.